BMC Cancer, 2006 Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping +5 more
doaj +1 more source
Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
Thoracic Cancer, 2020 Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj +1 more source
Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer [PDF]
, 2016 The small GTPase Rab25 has been functionally linked to tumour progression and aggressiveness in ovarian cancer and promotes invasion in three-dimensional environments.
Chalmers, Anthony J. +3 more
core +1 more source
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1 [PDF]
, 2009 A systematic review of cell models of acquired drug resistance not involving genetic manipulation showed that 80% of cell models had an inverse resistance relationship between cisplatin and paclitaxel[1].
Davey, Ross, Stordal, Britta
core +1 more source
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin- induced cytotoxicity [PDF]
, 2014 BACKGROUND: Antiprogestin compounds have been shown to be effective in blocking the growth of ovarian cancer cells of different genetic backgrounds.
Gamarra Luques, Carlos Diego +3 more
core +1 more source
Frontiers in Pharmacology, 2017 Resistance to platinum-based chemotherapy is one of the most important reasons for treatment failure in advanced non-small cell lung cancer, but the underlying mechanism is extremely complex and unclear.
Aman Wang +7 more
doaj +1 more source
New trends for metal complexes with anticancer activity [PDF]
, 2008 Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is,
Ang +56 more
core +1 more source
Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells [PDF]
Cells, 2019 The efficiency of cisplatin (CDDP) is significantly hindered by the development of resistance during the treatment course. To gain a detailed understanding of the molecular mechanisms underlying the development of cisplatin resistance, we comparatively analyzed established a CDDP-resistant neuroblastoma cell line (UKF-NB-4CDDP) and its susceptible ...
Miguel Angel Merlos Rodrigo +6 more
openaire +4 more sources
Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells [PDF]
, 2010 Inhibition or downregulation of Bcl-2 represents a new therapeutic approach to by-pass chemoresistance in cancer cells. Therefore, we explored the potential of this approach in breast cancer cells.
A Letai +34 more
core +1 more source
Frontiers in Cell and Developmental Biology, 2020 Cisplatin [cis-diamminedichloroplatinum (II)] is a platinum-based anticancer drug widely used for the treatment of various cancers. It forms interstrand and intrastrand cross-linking with DNA and block DNA replication, resulting in apoptosis.
Takahiro Shimizu +2 more
doaj +1 more source